US FDA's Breakthrough Program Needs Higher Standard For Comparators, NEJM Says
Harvard Medical School researchers call for inclusion of off-label drugs, accelerated approvals, and dietary supplements in the definition of 'existing therapies.'
You may also be interested in...
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.
Fueled by Congress, media attention, reevaluation of Acadia's Parkinson's drug feels like a scandal from pharma's primary care era – but is also a glimpse of what things might look like for industry if Democrats retake the House.
Taking on critics who say it is too quick to award accelerated approval based on surrogate endpoints and limited safety data, agency's 25-year review shows cancer drugs receiving accelerated approval generally have twice the amount of safety data as efficacy, and more than half have confirmed clinical benefit after approval.